Adial stockholders approve 4x increase in equity plan shares to 2M; directors re-elected

ADIAL PHARMACEUTICALS, INC.

Amendment No. 6 to 2017 Equity Incentive Plan approved, raising authorized shares from 500,000 to 2,000,000.
J. Kermit Anderson and James W. Newman Jr. re-elected as Class III directors through 2027.
Marcum LLP ratified as independent auditor for fiscal year ending December 31, 2024.
Advisory vote on executive compensation approved; board sets future advisory vote every three years.
Broker non-votes of ~2.3M shares on director election and plan amendment, reflecting significant institutional abstentions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.